" class="no-js "lang="en-US"> Cerner Enviza, an Oracle company - Medtech Alert
Friday, December 01, 2023

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Cerner Enviza

Cerner Enviza, an Oracle company

About Cerner Enviza, an Oracle company

Cerner Enviza, an Oracle company
On December 20, 2021, Oracle and Cerner jointly announced an agreement for Oracle to acquire Cerner through an all-cash tender offer for $95.00 per share, or approximately $28.3 billion in equity value. Cerner is a leading provider of digital information systems used within hospitals and health systems to enable medical professionals to deliver better healthcare to individual patients and communities.

Related Story

Diseases

 Freenome Launches Its First Study for the Detection of Multiple Cancers That Pairs Multiomics With Real-World Data | Pharmtech Focus

Freenome Launches Its First Study for the Detection of Multiple Cancers That Pairs Multiomics With Real-World Data

September 8 2022

Freenome, a privately held biotech company, today announced the launch of the Sanderson Study, the […]